Relationship Between Severity of Adverse Events of Afatinib and Its Pharmacokinetics and Pharmacogenomics for EGFR Mutation-Positive Non-Small Cell Lung Cancer

被引：0
|
作者：
Gomyo, T. [1 ]
Iihara, H. [2 ]
Hayashi, H. [3 ]
Endo, J. [1 ]
Ito, F. [1 ]
Yansase, K. [1 ]
Kaito, D. [1 ]
Sasaki, Y. [1 ]
Sakai, C. [1 ]
Fukuda, Y. [3 ]
Hirose, C. [2 ]
Sugiyama, T. [1 ]
Suzuki, A. [2 ]
Ohno, Y. [1 ]
机构：
[1] Gifu Univ, Grad Sch Med, Gifu, Japan
[2] Gifu Univ Hosp, Gifu, Japan
[3] Gifu Pharmaceut Univ, Gifu, Japan
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3936
引用
收藏
页数：1
相关论文
共 50 条
  • [41] ROLE OF QUIESCENCE CANCER STEM CELLS IN THE GEFITINIB RESISTANCE IN EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
    Hidayat, Moulid
    Takahashi, Fumiyuki
    Tajima, Ken
    Nurwidya, Fariz
    Wirawan, Aditya
    Kanemaru, Ryota
    Koinuma, Yoshika
    Hayakawa, Daisuke
    Tajima, Manabu
    Matsumoto, Naohisa
    Kanamori, Koichiro
    Takeda, Ikuko
    Kato, Motoyasu
    Kobayashi, Isao
    Shimada, Naoko
    Takahashi, Kazuhisa
    RESPIROLOGY, 2017, 22 : 18 - 19
  • [42] Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Isomoto, Kohsuke
    Haratani, Koji
    Hayashi, Hidetoshi
    Shimizu, Shigeki
    Tomida, Shuta
    Niwa, Takashi
    Yokoyama, Toshihide
    Fukuda, Yasushi
    Chiba, Yasutaka
    Kato, Ryoji
    Tanizaki, Junko
    Tanaka, Kaoru
    Takeda, Masayuki
    Ogura, Takashi
    Ishida, Tadashi
    Ito, Akihiko
    Nakagawa, Kazuhiko
    CLINICAL CANCER RESEARCH, 2020, 26 (08) : 2037 - 2046
  • [43] Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study
    Brueckl, Wolfgang M.
    Reck, Martin
    Schaefer, Harald
    Neben, Kai
    Griesinger, Frank
    Rawluk, Justyna
    Krueger, Stefan
    Kokowski, Konrad
    Ficker, Joachim H.
    Moeller, Miriam
    Schueler, Andrea
    Laack, Eckart
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (01)
  • [44] Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC).
    Yang, James Chih-Hsin
    Ahn, Myung-Ju
    Dickgreber, Nicolas J.
    Halmos, Balazs
    Hirsh, Vera
    Hochmair, Maximilian J.
    Levy, Benjamin Philip
    De Marinis, Filippo
    Mok, Tony
    O'Byrne, Kenneth
    Okamoto, Isamu
    Schuler, Martin H.
    Sebastian, Martin
    Shah, Riyaz N. H.
    Tan, Eng-Huat
    Yamamoto, Nobuyuki
    Marten, Angela
    Massey, Dan
    Wind, Sven
    Carbone, David Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study
    Tamiya, Akihiro
    Tamiya, Motohiro
    Nishihara, Takashi
    Shiroyama, Takayuki
    Nakao, Keiko
    Tsuji, Taisuke
    Takeuchi, Naoko
    Isa, Shun-Ichi
    Omachi, Naoki
    Okamoto, Norio
    Suzuki, Hidekazu
    Okishio, Kyoichi
    Iwazaki, Ayano
    Imai, Kimie
    Hirashima, Tomonori
    Atagi, Shinji
    ANTICANCER RESEARCH, 2017, 37 (08) : 4177 - 4182
  • [46] Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
    Passaro, A.
    Yang, J. C.
    Ahn, M.
    Dickgreber, N. J.
    Halmos, B.
    Hirsh, V.
    Hochmair, M. J.
    Levy, B. P.
    de Marinis, F.
    Mok, T.
    O'Byrne, K.
    Okamoto, I.
    Schuler, M.
    Sebastian, M.
    Shah, R.
    Tan, E.
    Yamamoto, N.
    Maerten, A.
    Wind, S.
    Carbone, D. P.
    ANNALS OF ONCOLOGY, 2015, 26 : 77 - 77
  • [47] Original Research Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancer
    Mizugaki, Hidenori
    Oizumi, Satoshi
    Fujita, Yuka
    Harada, Toshiyuki
    Nakahara, Yoshiro
    Takashina, Taichi
    Ko, Ryo
    Watanabe, Kageaki
    Hotta, Takamasa
    Minemura, Hiroyuki
    Saeki, Sho
    Asahina, Hajime
    Nakamura, Keiichi
    Nakamura, Hiromi
    Hosoda, Fumie
    Yagishita, Shigehiro
    Hamada, Akinobu
    EUROPEAN JOURNAL OF CANCER, 2022, 160 : 227 - 234
  • [48] Impact of afatinib dosing on safety and efficacy in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) in a real-world setting
    Halmos, Balazs
    Tan, Eng-Huat
    Soo, Ross
    Cadranel, Jacques
    Lee, Min Ki
    Foucher, Pascal
    Hsia, Te-Chun
    Hochmair, Maximilian
    Griesinger, Frank
    Hida, Toyoaki
    Kim, Edward
    Melosky, Barbara
    Maerten, Angela
    Carcereny, Enric
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 160 - 161
  • [49] Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data
    Choi, Juwhan
    Choi, Chang Min
    Chang, Yoon Soo
    Lee, Kye Young
    Kim, Seung Joon
    Yang, Sei Hoon
    Ryu, Jeong Seon
    Lee, Jeong Eun
    Lee, Shin Yup
    Park, Ji Young
    Kim, Young-Chul
    Oh, In-Jae
    Jung, Chi Young
    Lee, Sang Hoon
    Yoon, Seong Hoon
    Lee, Sung Yong
    Jang, Tae Won
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (11) : 2275 - 2282
  • [50] Epidermal Growth Factor Receptor (EGFR)-Mediated Adverse Events (AEs) in Patients (pts) With EGFR-Mutation Positive (EGFR M plus ) Non-Small Cell Lung Cancer (NSCLC) Treated With Afatinib (A)
    Wu, Y.
    Geater, S. L.
    Mok, T.
    O'Byrne, K. J.
    Schuler, M. H.
    Sequist, L. V.
    Yang, J. C.
    Massey, D.
    O'Brien, D.
    Zazulina, V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S41 - S41
12345